Pharming Group (PHAR) Company Report

Pharming reported strong Q3 2025 results and raised its revenue guidance, driven by the continued growth of its two assets, RUCONEST and Joenja, which grew 29% in Q4 2024 year on year and 35%, respectively.
The company anticipates significant growth for Joenja, expecting FDA label expansion for the pediatric APDS population by end of January 2026, which could add 30% to its potential, and projects the reclassification of approximately 250 VUS patients over time, increasing APDS potential by 50%.
Pharming acquired Abliva, adding KL1333 for primary mitochondrial disease to its pipeline, an asset with more than a billion-dollar potential that is currently in registrational phase 2 trials and has undergone a positive futility analysis.
To optimize capital allocation and drive value, Pharming has cut 20% of its G&A headcounts and appointed Kenneth Lenertz as its new CFO.

Nov 19, 2025, 10:00 AM

Pharming Reports Strong Q3, Highlights Growth Drivers for RUCONEST and Joenja, and Discusses KL1333 Acquisition

PHAR

Guidance Update

Revenue Acceleration/Inflection

M&A

Pharming reported strong Q3 results and raised revenue guidance, driven by the continued double-digit growth of its two assets, RUCONEST and Joenja.
RUCONEST grew 29% in Q4 year-on-year, maintaining its position for severe HAE patients, while the company exited non-U.S. markets due to financial unsustainability.
Joenja grew 35% in Q4 year-on-year and is projected to become a billion-dollar drug, with significant growth opportunities including pediatric indication expansion (expected by end of January) and reclassification of 250 VUS patients.
Pharming acquired Abliva for KL1333, a drug for Primary Mitochondrial Disease (PMD) with billion-dollar potential currently in registrational Phase II trials, which has undergone a positive futility analysis.
The company is focused on optimal capital allocation, including a 20% cut in G&A headcounts, and recently attracted a new CFO, Kenneth Lynard.

Nov 19, 2025, 10:00 AM

Pharming Reports Strong Q3 Results, Raises Guidance, and Outlines Growth Strategies

PHAR

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

Pharming reported strong third-quarter results and raised its revenue guidance, driven by RUCONEST growing 29% year-on-year in Q4 and Joenja growing 35%.
The company is focused on Joenja's high-growth potential, with expected FDA approval for pediatric expansion by the end of January, and the reclassification of VUS patients projected to increase APDS potential by 50%.
Pharming acquired KL1333 for primary mitochondrial disease, a registrational Phase 2 asset with billion-dollar potential that has undergone a positive futility analysis.
To optimize capital allocation, Pharming cut 20% of its G&A headcounts and appointed Kenneth Lenertz as the new CFO.

Nov 19, 2025, 10:00 AM

Pharming Group N.V. Reports Strong Q3 2025 Results and Raises Full-Year Revenue Guidance

PHAR

Earnings

Guidance Update

Product Launch

Pharming Group N.V. reported Q3 2025 total revenues of $97.3 million, a 30% increase year-over-year, with operating profit reaching $16.0 million.
The company raised its full-year 2025 total revenue guidance to $365-$375 million from the previous $335-$350 million, projecting 23%-26% growth.
Both commercial assets contributed significantly, with Ruconest revenue up 29% to $82 million and Joenja revenue increasing 35% to $15.1 million in Q3 2025.
The FDA granted priority review for Joenja's label expansion to 4- to 11-year-old children, with an approval date set for January 31, 2026, which is expected to be a significant growth driver.
Pharming is optimizing capital allocation through G&A headcount reductions and plans to complete the withdrawal of Ruconest from some European markets by the first half of 2026 due to financial sustainability.

Nov 6, 2025, 12:30 PM

Pharming Group N.V. Reports Strong Q3 2025 Financial Results and Raises Full-Year Revenue Guidance

PHAR

Earnings

Guidance Update

Revenue Acceleration/Inflection

Total revenues for Q3 2025 increased by 30% to US$97.3 million, with RUCONEST® revenue up 29% to US$82.2 million and Joenja® revenue up 35% to US$15.1 million compared to Q3 2024.
Operating profit for Q3 2025 surged by 285% to US$15.8 million, and the company generated US$32.0 million in cash flow from operations during the quarter.
Pharming raised its 2025 total revenue guidance to between US$365 million and US$375 million and received FDA priority review for leniolisib for children aged 4 to 11, with a decision expected by January 2026.

Nov 6, 2025, 11:04 AM

Pharming Group N.V. Implements Organizational Restructuring and Provides G&A Expense Reduction Update

PHAR

Layoffs

Guidance Update

Pharming Group N.V. announced the implementation of an organizational restructuring, which includes a 20% net reduction in non-commercial and non-medical headcount, primarily at its Netherlands headquarters.
The company remains on track to reduce total general and administrative (G&A) expenses by 15% or US$10 million annually.
Pharming anticipates recording approximately $7 million in one-time restructuring costs in the fourth quarter of 2025 related to the headcount reduction.

Oct 6, 2025, 3:45 PM

Pharming Group Announces FDA Acceptance and Priority Review for Leniolisib sNDA

PHAR

Product Launch

New Projects/Investments

Pharming Group N.V. announced the U.S. FDA's acceptance of its supplemental New Drug Application (sNDA) for leniolisib to treat children aged 4 to 11 years with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS).
The FDA granted Priority Review for the sNDA, with a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.
If approved, leniolisib would be the first and only treatment indicated for children aged 4 to 11 years with APDS, building on its existing U.S. FDA approval for patients 12 years of age and older.